Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

NCT05897372 · Terminated

Last updated 2026-05-28

This clinical trial tests whether a treatment can significantly reduce protein in the urine of people with confirmed diabetic kidney disease.

Status Terminated Stopped early and will not restart.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 1 person

Who can join Ages 18+ · all sexes

Timeline Started 2023-08 · est. completion 2024-09

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT05897372 ↗

Description as written by the study sponsor.

The purpose of this trial is to investigate the feasibility and safety of implementing a protocol-based treatment aggressively targeting albuminuria in subjects with biopsy-proven diabetic nephropathy and severely elevated albuminuria. If this approach is feasible, the results of the trial will inform the design of a large-scale randomized clinical trial to evaluate the effect of this treatment on hard kidney endpoints (initiation of dialysis, kidney transplantation, and death from kidney failure) in subjects with biopsy-proven diabetic nephropathy and severely elevated albuminuria.

Treatments tested

ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib Drug

Standard of care for diabetic kidney disease.

Main thing measured	urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline
Sponsor	Iain Bressendorff
Conditions studied	Diabetic Kidney Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05897372 ↗